Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Price
Target price
€155.80

€155.80

-0.380%
-0.6
-0.380%
€170.00

€170.00

 
Latest predictions
€185.00
16.10.20
buy
-
05.10.20
buy
€160.00
06.09.20
buy
€188.00
01.09.20
buy
-
31.08.20
€170.00
18.08.20
buy
Your prediction

Shop Apotheke Europe NV Stock

The price for the Shop Apotheke Europe NV stock decreased slightly today. Compared to yesterday there is a change of -€0.600 (-0.380%).
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of €170.00 there is a slightly positive potential of 9.114% for Shop Apotheke Europe NV compared to the current price of €155.80.

Pros and Cons of Shop Apotheke Europe NV in the next few years

Pros
2
Very Future proof/growth oriented business model
2
Well known brand
2
Revenue growth > 30% per year expected
2
Could be very worthwhile Investment >20% year
1
Very positive Cash Flow expected
Cons
0
-

Comments

Sell Shop Apotheke Europe NV

Buy Shop Apotheke Europe NV

Buy Shop Apotheke Europe NV

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Shop Apotheke Europe NV Stock

Trading Shop Apotheke Europe NV

Trading Shop Apotheke Europe NV

New thread Forum

News

DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ANNOUNCES REDEMPTION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ANNOUNCES REDEMPTION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ENDS DISCUSSIONS AND ANNOUNCES CLEAN-UP OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ENDS DISCUSSIONS AND ANNOUNCES CLEAN-UP OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-News: SHOP APOTHEKE EUROPE grows by 39.7% in Q3.
DGAP-News: SHOP APOTHEKE EUROPE grows by 39.7% in Q3.
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V.:
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V.:
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ANNOUNCES TO START DISCUSSIONS OF A POSSIBLE EARLIER CONVERSION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-Adhoc: SHOP APOTHEKE EUROPE N.V. ANNOUNCES TO START DISCUSSIONS OF A POSSIBLE EARLIER CONVERSION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.
DGAP-News: SHOP APOTHEKE EUROPE promoted to MDAX.
DGAP-News: SHOP APOTHEKE EUROPE promoted to MDAX.
DGAP-News: SHOP APOTHEKE EUROPE: 42% growth and significantly improved bottom line in Q2; adjusted Q2 EBITDA margin 2.7%.
DGAP-News: SHOP APOTHEKE EUROPE: 42% growth and significantly improved bottom line in Q2; adjusted Q2 EBITDA margin 2.7%.
DGAP-Adhoc: SHOP APOTHEKE EUROPE raises full year 2020 guidance.
DGAP-Adhoc: SHOP APOTHEKE EUROPE raises full year 2020 guidance.
DGAP-News: SHOP APOTHEKE EUROPE: GROWTH ACCELERATES FURTHER TO 42% IN Q2. H1 GROWTH IS 37% NOW.
DGAP-News: SHOP APOTHEKE EUROPE: GROWTH ACCELERATES FURTHER TO 42% IN Q2. H1 GROWTH IS 37% NOW.
DGAP-News: SHOP APOTHEKE EUROPE achieves positive EBITDA ahead of schedule and increases sales by 33% in Q1.
DGAP-News: SHOP APOTHEKE EUROPE achieves positive EBITDA ahead of schedule and increases sales by 33% in Q1.
DGAP-News: SHOP APOTHEKE EUROPE N.V.: Annual General Meeting approves all items on the agenda.
DGAP-News: SHOP APOTHEKE EUROPE N.V.: Annual General Meeting approves all items on the agenda.